{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:02:02Z","timestamp":1784786522103,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00213-021-05788-w","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T08:37:40Z","timestamp":1613291860000},"page":"1563-1573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Long acting aripiprazole influences cognitive functions in recent onset schizophrenia"],"prefix":"10.1007","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-6411","authenticated-orcid":false,"given":"Vjekoslav","family":"Peitl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"\u0160tefanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivona","family":"Orlovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Culej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Renduli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krunoslav","family":"Mate\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalibor","family":"Karlovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,13]]},"reference":[{"issue":"2","key":"5788_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.neurobiolaging.2004.03.007","volume":"26","author":"OP Almeida","year":"2005","unstructured":"Almeida OP, Flicker L, Lautenschlager NT, Leedman P, Vasikaran S, van Bockxmeer FM (2005) Contribution of the MTHFR gene to the causal pathway for depression, anxiety and cognitive impairment in later life. Neurobiol Aging 26(2):251\u2013257. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2004.03.007","journal-title":"Neurobiol Aging"},{"issue":"5","key":"5788_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/sj.mp.4001973","volume":"12","author":"JH Barnett","year":"2007","unstructured":"Barnett JH, Jones PB, Robbins TW, M\u00fcller U (2007) Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol Psychiatry 12(5):502\u2013509. https:\/\/doi.org\/10.1038\/sj.mp.4001973","journal-title":"Mol Psychiatry"},{"issue":"11","key":"5788_CR3","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40263-012-0003-4","volume":"26","author":"C Bervoets","year":"2012","unstructured":"Bervoets C, Morrens M, Vansteelandt K, Kok F, de Patoul A, Halkin V, Pitsi D, Constant E, Peuskens J, Sabbe B (2012) Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study. CNS Drugs 26(11):975\u2013982. https:\/\/doi.org\/10.1007\/s40263-012-0003-4","journal-title":"CNS Drugs"},{"issue":"5","key":"5788_CR4","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1007\/s12325-017-0507-x","volume":"34","author":"E Biagi","year":"2017","unstructured":"Biagi E, Capuzzi E, Colmegna F, Mascarini A, Brambilla G, Ornaghi A, Santambrogio J, Clerici M (2017) Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly. Adv Ther 34(5):1036\u20131048. https:\/\/doi.org\/10.1007\/s12325-017-0507-x","journal-title":"Adv Ther"},{"key":"5788_CR5","doi-asserted-by":"publisher","unstructured":"Bilder RM, Reiter G, Bates J, Lencz T, Szeszko P, Goldman RS, Robinson D, Lieberman JA, Kane JM (2006) Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol 28(2):270\u2013282. https:\/\/doi.org\/10.1080\/13803390500360554","DOI":"10.1080\/13803390500360554"},{"issue":"4","key":"5788_CR6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/schbul\/sbt085","volume":"40","author":"E Bora","year":"2014","unstructured":"Bora E, Murray RM (2014) Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: do the cognitive deficits progress over, or after, the onset of psychosis? Schizophr Bull 40(4):744\u2013755. https:\/\/doi.org\/10.1093\/schbul\/sbt085","journal-title":"Schizophr Bull"},{"issue":"1-2","key":"5788_CR7","first-page":"83","volume":"18","author":"N Bo\u017eina","year":"2006","unstructured":"Bo\u017eina N, Mihaljevi\u0107-Pele\u0161 A, Sagud M, Jakovljevi\u0107 M, Serti\u0107 J (2006) Serotonin transporter polymorphism in Croatian patients with major depressive disorder. Psychiatr Danub 18(1-2):83\u201389","journal-title":"Psychiatr Danub"},{"issue":"2","key":"5788_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1600-0447.2008.01273.x","volume":"119","author":"J Contreras","year":"2009","unstructured":"Contreras J, Hare L, Camarena B, Glahn D, Dassori A, Medina R, Contreras S, Ramirez M, Armas R, Munoz R, Mendoza R, Raventos H, Ontiveros A, Nicolini H, Palmer R, Escamilla M (2009) The serotonin transporter 5-HTTPR polymorphism is associated with current and lifetime depression in persons with chronic psychotic disorders. Acta Psychiatr Scand 119(2):117\u2013127. https:\/\/doi.org\/10.1111\/j.1600-0447.2008.01273.x","journal-title":"Acta Psychiatr Scand"},{"key":"5788_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/NDT.S189245","volume":"15","author":"R Di Lorenzo","year":"2019","unstructured":"Di Lorenzo R, Ferri P, Cameli M, Rovesti S, Piemonte C (2019) Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatr Dis Treat 15:183\u2013198. https:\/\/doi.org\/10.2147\/NDT.S189245","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"5788_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.neurobiolaging.2005.01.003","volume":"27","author":"J Durga","year":"2006","unstructured":"Durga J, van Boxtel MP, Schouten EG, Bots ML, Kok FJ, Verhoef P (2006) Folate and the methylenetetrahydrofolate reductase 677C\u2192T mutation correlate with cognitive performance. Neurobiol Aging 27(2):334\u2013343. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2005.01.003","journal-title":"Neurobiol Aging"},{"issue":"12","key":"5788_CR11","doi-asserted-by":"publisher","first-page":"6917","DOI":"10.1073\/pnas.111134598","volume":"98","author":"MF Egan","year":"2001","unstructured":"Egan MF, Goldberg TE, Kolachana BS, Callicott JH (2001) Effect of COMT Val108\/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 98(12):6917\u20136922. https:\/\/doi.org\/10.1073\/pnas.111134598","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5788_CR12","unstructured":"First MB, Williams JBW, Karg RS (2015) Structured clinical interview for DSM-5 research version (SCID-5 for DSM-5, Research Version; SCID-5-RV). American Psychiatric Publishing, Arlington."},{"issue":"1","key":"5788_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/ng0595-111","volume":"10","author":"P Frosst","year":"1995","unstructured":"Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuve LP, Rozen R (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111\u2013113. https:\/\/doi.org\/10.1038\/ng0595-111","journal-title":"Nat Genet"},{"key":"5788_CR14","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3389\/fpsyt.2019.00935","volume":"10","author":"G Giordano","year":"2020","unstructured":"Giordano G, Tomassini L, Cuomo I, Amici E, Perrini F, Callovini G, Carannante A, Kotzalidis GD, De Filippis S (2020) Aripiprazole long-acting injection during first episode schizophrenia-an exploratory analysis. Front Psychiatry 10:935. https:\/\/doi.org\/10.3389\/fpsyt.2019.00935","journal-title":"Front Psychiatry"},{"issue":"2","key":"5788_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.neulet.2011.08.027","volume":"503","author":"X Guo","year":"2011","unstructured":"Guo X, Zhai J, Wei Q, Twamley EW, Jin H, Fang M, Hu M, Zhao J (2011) Neurocognitive effects of first and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neurosci Lett 503(2):141\u2013146. https:\/\/doi.org\/10.1016\/j.neulet.2011.08.027","journal-title":"Neurosci Lett"},{"issue":"11","key":"5788_CR16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/WNR.0b013e32830867ad","volume":"19","author":"DH Han","year":"2008","unstructured":"Han DH, Park DB, Choi TY, Joo SY, Lee MK, Park BRG, Nishimura R, Chu CC, Renshaw PF (2008) Effects of brain-derived neurotrophic factor-catecholamine-O-methyltransferase gene interaction on schizophrenic symptoms. Neuroreport 19(11):1155\u20131158. https:\/\/doi.org\/10.1097\/WNR.0b013e32830867ad","journal-title":"Neuroreport"},{"issue":"6","key":"5788_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jpsychires.2012.02.013","volume":"46","author":"H Hori","year":"2012","unstructured":"Hori H, Yoshimura R, Katsuki A, Hayashi K, Ikenouchi-Sugita A, Umene-Nakano W, Jun N (2012) The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. J Psychiatr Res 46(6):757\u2013761. https:\/\/doi.org\/10.1016\/j.jpsychires.2012.02.013","journal-title":"J Psychiatr Res"},{"key":"5788_CR18","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.2147\/NDT.S164647","volume":"14","author":"H Kaneko","year":"2018","unstructured":"Kaneko H, Miura I, Kanno-Nozaki K, Horikoshi S, Hino M, Yabe H (2018) COMT Val 108\/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia. Neuropsychiatr Dis Treat 14:1657\u20131663. https:\/\/doi.org\/10.2147\/NDT.S164647","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"5788_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opfer LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261\u2013276. https:\/\/doi.org\/10.1093\/schbul\/13.2.261","journal-title":"Schizophr Bull"},{"issue":"3","key":"5788_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s00213-006-0428-x","volume":"187","author":"RS Kern","year":"2006","unstructured":"Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, Ali M, Marcus R (2006) The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology 187(3):312\u2013320. https:\/\/doi.org\/10.1007\/s00213-006-0428-x","journal-title":"Psychopharmacology"},{"key":"5788_CR21","doi-asserted-by":"publisher","first-page":"CD006569","DOI":"10.1002\/14651858.CD006569.pub5","volume":"2","author":"P Khanna","year":"2014","unstructured":"Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, Leucht S, Xia J (2014) Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2:CD006569. https:\/\/doi.org\/10.1002\/14651858.CD006569.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"5788_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.neulet.2013.01.012","volume":"537","author":"D Kontis","year":"2013","unstructured":"Kontis D, Theochari E, Fryssira H, Kleisas S, Sofocleous C, Andreopoulou A, Kalogerakou S, Gazi A, Boniatsi L, Chaidemenos A, Tsaltas E (2013) COMT and MTHFR polymorphisms interaction on cognition in schizophrenia: an exploratory study. Neurosci Lett 537:17\u201322. https:\/\/doi.org\/10.1016\/j.neulet.2013.01.012","journal-title":"Neurosci Lett"},{"issue":"5","key":"5788_CR23","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/ajmg.b.31077","volume":"153B","author":"TI Konneker","year":"2010","unstructured":"Konneker TI, Crowley JJ, Quackenbush CR, Keefe RSE, Perkins DO, Scott Stroup T, Lieberman JA, van den Oord E, Sullivan PF (2010) No association of the serotonin transporter polymorphisms 5HTTLPR and rs25531 with schizophrenia or neurocognition. Am J Med Genet B Neuropsychiatr Genet 153B(5):1115\u20131117. https:\/\/doi.org\/10.1002\/ajmg.b.31077","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"2","key":"5788_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.20471\/dec.2020.56.02.03","volume":"56","author":"I Kri\u017eanac","year":"2020","unstructured":"Kri\u017eanac I, Mate\u0161i\u0107 K, Karlovi\u0107 D (2020) 5 - KOG Test performance on patients with schizophrenia, alcoholism and depression. Archives of Psychiatry Research 56(2):143\u2013154. https:\/\/doi.org\/10.20471\/dec.2020.56.02.03","journal-title":"Archives of Psychiatry Research"},{"issue":"3","key":"5788_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00008571-199606000-00007","volume":"6","author":"HM Lachman","year":"1996","unstructured":"Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM (1996) Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6(3):243\u2013250. https:\/\/doi.org\/10.1097\/00008571-199606000-00007","journal-title":"Pharmacogenetics"},{"issue":"1","key":"5788_CR26","first-page":"32","volume":"4","author":"JG Lee","year":"2006","unstructured":"Lee JG, Lee JH, Ha EK, Kim MC, Kim YH (2006) Switching patients with chronic schizophrenia to aripiprazole: the improvement in cognitive function. Clin Psychopharmacol Neurosci 4(1):32\u201339","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"2","key":"5788_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.9758\/cpn.2013.11.2.60","volume":"11","author":"BJ Lee","year":"2013","unstructured":"Lee BJ, Lee SJ, Kim MK, Lee JG, Park SW, Kim GM, Kim YH (2013) Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin Psychopharmacol Neurosci 11(2):60\u201366. https:\/\/doi.org\/10.9758\/cpn.2013.11.2.60","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"1-2","key":"5788_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.schres.2015.07.037","volume":"168","author":"JP Lindenmayer","year":"2015","unstructured":"Lindenmayer JP, Khan A, Lachman H, McGurk SR, Goldring A, Thanju A, Kaushik S (2015) COMT genotype and response to cognitive remediation in schizophrenia. Schizophr Res 168(1-2):279\u2013284. https:\/\/doi.org\/10.1016\/j.schres.2015.07.037","journal-title":"Schizophr Res"},{"issue":"4","key":"5788_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.euroneuro.2013.12.009","volume":"24","author":"A Maat","year":"2014","unstructured":"Maat A, Cahn W, Gijsman HJ, Hovens JE, Kahl RS, Aleman A (2014) Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia. Eur Neuropsychopharmacol 24(4):575\u2013584. https:\/\/doi.org\/10.1016\/j.euroneuro.2013.12.009","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2-3","key":"5788_CR30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00213-010-1926-4","volume":"213","author":"K Madsen","year":"2011","unstructured":"Madsen K, Erritzoe D, Mortensen EL, Gade A, Madsen J, Baar\u00e9 W, Knudsen GM, Hasselbalch SG (2011) Cognitive function is related to fronto-striatal serotonin transporter levels--a brain PET study in young healthy subjects. Psychopharmacology 213(2-3):573\u2013581. https:\/\/doi.org\/10.1007\/s00213-010-1926-4","journal-title":"Psychopharmacology"},{"issue":"10","key":"5788_CR31","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/ijnp\/pyz043","volume":"22","author":"J Mallet","year":"2019","unstructured":"Mallet J, Gorwood P, Le Strat Y, Dubertret C (2019) Major depressive disorder (MDD) and schizophrenia- addressing unmet needs with partial agonists at the D2 receptor: a review. Int J Neuropsychopharmacol 22(10):651\u2013664. https:\/\/doi.org\/10.1093\/ijnp\/pyz043","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1-3","key":"5788_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.schres.2008.02.011","volume":"102","author":"I Mata","year":"2008","unstructured":"Mata I, Perez-Iglesias R, Pelayo-Teran JM, Rodr\u00edguez-Sanchez JM, Gonzalez-Blanch C, Carrasco-Marin E, Vazquez-Barquero JL, Crespo-Facorro B (2008) Lack of influence of COMT Val158Met genotype on cognition in first-episode non-affective psychosis. Schizophr Res 102(1-3):206\u2013209. https:\/\/doi.org\/10.1016\/j.schres.2008.02.011","journal-title":"Schizophr Res"},{"issue":"6","key":"5788_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/pcn.12147","volume":"68","author":"Y Matsuda","year":"2014","unstructured":"Matsuda Y, Sato S, Iwata K, Furukawa S, Hatsuse N, Watanabe Y, Anzai N, Kishimoto T, Ikebuchi E (2014) Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia. Psychiatry Clin Neurosci 68(6):425\u2013431. https:\/\/doi.org\/10.1111\/pcn.12147","journal-title":"Psychiatry Clin Neurosci"},{"issue":"3","key":"5788_CR34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1037\/a0014708","volume":"23","author":"RI Mesholam-Gately","year":"2009","unstructured":"Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ (2009) Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 23(3):315\u2013336. https:\/\/doi.org\/10.1037\/a0014708","journal-title":"Neuropsychology"},{"key":"5788_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1745-0179-4-24","volume":"4","author":"A Mucci","year":"2008","unstructured":"Mucci A, Piegari G, Galderisi S (2008) Cognitive-enhancing effects of aripiprazole: a case report. Clin Pract Epidemiol Ment Health 4:24. https:\/\/doi.org\/10.1186\/1745-0179-4-24","journal-title":"Clin Pract Epidemiol Ment Health"},{"issue":"1","key":"5788_CR36","doi-asserted-by":"publisher","first-page":"e0170147","DOI":"10.1371\/journal.pone.0170147","volume":"12","author":"I Nkam","year":"2017","unstructured":"Nkam I, Ramoz N, Breton F, Mallet J, Gorwood P, Dubertret C (2017) Impact of DRD2\/ANKK1 and COMT polymorphisms on attention and cognitive functions in schizophrenia. PLoS One 12(1):e0170147. https:\/\/doi.org\/10.1371\/journal.pone.0170147","journal-title":"PLoS One"},{"issue":"1-3","key":"5788_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.schres.2009.03.039","volume":"112","author":"C Pantelis","year":"2009","unstructured":"Pantelis C, Wood SJ, Proffitt TM, Testa R, Mahony K, Brewer WJ, Buchanan J-A, Velakoulis D, McGorry PD (2009) Attentional set-shifting ability in first-episode and established schizophrenia: relationship to working memory. Schizophr Res 112(1-3):104\u2013113. https:\/\/doi.org\/10.1016\/j.schres.2009.03.039","journal-title":"Schizophr Res"},{"key":"5788_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.pnpbp.2017.04.011","volume":"77","author":"V Peitl","year":"2017","unstructured":"Peitl V, \u0160tefanovi\u0107 M, Karlovi\u0107 D (2017) Depressive symptoms in schizophrenia and dopamine and serotonin gene polymorphisms. Prog Neuro-Psychopharmacol Biol Psychiatry 77:209\u2013215. https:\/\/doi.org\/10.1016\/j.pnpbp.2017.04.011","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"2","key":"5788_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1055\/s-0029-1239539","volume":"43","author":"M Riedel","year":"2010","unstructured":"Riedel M, Spellmann I, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, Matz J, Seem\u00fcller F, Obermeier M, Severus E, Engel RR, M\u00fcller N, M\u00f6ller H-J (2010) Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry 43(2):50\u201357. https:\/\/doi.org\/10.1055\/s-0029-1239539","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"5788_CR40","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/schbul\/sbv125","volume":"41","author":"DG Robinson","year":"2015","unstructured":"Robinson DG, Gallego JA, John M, Petrides G, Hassoun Y, Zhang J-P, Lopez L, Braga RJ, Sevy SM, Addington J, Kellner CH, Tohen M, Naraine M, Bennett N, Greenberg J, Lencz T, Correll CU, Kane JM, Malhotra AK (2015) A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. Schizophr Bull 41(6):1227\u20131236. https:\/\/doi.org\/10.1093\/schbul\/sbv125","journal-title":"Schizophr Bull"},{"issue":"6","key":"5788_CR41","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/ajmg.b.30684","volume":"147B","author":"JL Roffman","year":"2008","unstructured":"Roffman JL, Weiss AP, Deckersbach T, Freudenreich O, Henderson DC, Wong DH, Halsted CH, Goff DC (2008) Interactive effects of COMT Val108\/158Met and MTHFR C677 T on executive function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 147B(6):990\u2013995. https:\/\/doi.org\/10.1002\/ajmg.b.30684","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"5788_CR42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.nlm.2013.12.015","volume":"110","author":"R Schreiber","year":"2014","unstructured":"Schreiber R, Newman-Tancredi A (2014) Improving cognition in schizophrenia with antipsychotics that elicit neurogenesis through 5-HT(1A) receptor activation. Neurobiol Learn Mem 110:72\u201380. https:\/\/doi.org\/10.1016\/j.nlm.2013.12.015","journal-title":"Neurobiol Learn Mem"},{"issue":"5","key":"5788_CR43","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.avb.2008.06.003","volume":"13","author":"D Seo","year":"2008","unstructured":"Seo D, Patrick CJ, Kennealy PJ (2008) Role of serotonin and dopamine system interactions in the neurobiology of impulsive aggression and its comorbidity with other clinical disorders. Aggress Violent Behav 13(5):383\u2013395. https:\/\/doi.org\/10.1016\/j.avb.2008.06.003","journal-title":"Aggress Violent Behav"},{"issue":"4","key":"5788_CR44","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11065-018-9388-2","volume":"28","author":"JM Sheffield","year":"2018","unstructured":"Sheffield JM, Karcher NR, Barch DM (2018) Cognitive deficits in psychotic disorders: a lifespan perspective. Neuropsychol Rev 28(4):509\u2013533. https:\/\/doi.org\/10.1007\/s11065-018-9388-2","journal-title":"Neuropsychol Rev"},{"issue":"5","key":"5788_CR45","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S0924-9338(97)83297-X","volume":"12","author":"DV Sheehan","year":"1997","unstructured":"Sheehan DV, Lecrubier Y, Harnett Sheehan K, Janavs J, Weiller E, Bonara LI, Keskiner A, Schinka J, Knapp E, Sheehan MF, Dunbar GC (1997) The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 12(5):232\u2013241. https:\/\/doi.org\/10.1016\/S0924-9338(97)83297-X","journal-title":"Eur Psychiatry"},{"issue":"6","key":"5788_CR46","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/15622975.2016.1245441","volume":"18","author":"NE Steen","year":"2017","unstructured":"Steen NE, Aas M, Simonsen C, Dieset I, Tesli M, Nerhus M, Gardsjord E, M\u00f8rch R, Agartz I, Melle I, Ueland T, Spigset O, Andreassen OA (2017) Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders. World J Biol Psychiatry 18(6):471\u2013482. https:\/\/doi.org\/10.1080\/15622975.2016.1245441","journal-title":"World J Biol Psychiatry"},{"issue":"2-3","key":"5788_CR47","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.neulet.2005.09.067","volume":"393","author":"RD Strous","year":"2006","unstructured":"Strous RD, Lapidus R, Viglin D, Kotler M, Lachman HM (2006) Analysis of an association between the COMT polymorphism and clinical symptomatology in schizophrenia. Neurosci Lett 393(2-3):170\u2013173. https:\/\/doi.org\/10.1016\/j.neulet.2005.09.067","journal-title":"Neurosci Lett"},{"issue":"6","key":"5788_CR48","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/schbul\/sbv120","volume":"41","author":"JW Trampush","year":"2015","unstructured":"Trampush JW, Lencz T, DeRosse P, John M, Gallego JA, Petrides G, Hassoun Y, Zhang J-P, Addington J, Kellner CH, Tohen M, Burdick KE, Goldberg TE, Kane JM, Robinson DG, Malhotra AK (2015) Relationship of cognition to clinical response in first-episode schizophrenia spectrum disorders. Schizophr Bull 41(6):1237\u20131247. https:\/\/doi.org\/10.1093\/schbul\/sbv120","journal-title":"Schizophr Bull"},{"issue":"3","key":"5788_CR49","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3969\/j.issn.1673-5374.2013.03.011","volume":"8","author":"J Wang","year":"2013","unstructured":"Wang J, Hu M, Guo X, Wu R, Li L, Zhao J (2013) Cognitive effects of atypical antipsychotic drugs in first-episode drug-na\u00efve schizophrenic patients. Neural Regen Res 8(3):277\u2013286. https:\/\/doi.org\/10.3969\/j.issn.1673-5374.2013.03.011","journal-title":"Neural Regen Res"},{"issue":"3","key":"5788_CR50","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1017\/S146114570500516X","volume":"8","author":"ND Woodward","year":"2005","unstructured":"Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005) A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8(3):457\u2013472. https:\/\/doi.org\/10.1017\/S146114570500516X","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1-3","key":"5788_CR51","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.schres.2006.10.002","volume":"90","author":"ND Woodward","year":"2007","unstructured":"Woodward ND, Jayathilake K, Meltzer HY (2007) COMT val108\/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 90(1-3):86\u201396. https:\/\/doi.org\/10.1016\/j.schres.2006.10.002","journal-title":"Schizophr Res"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-021-05788-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T04:06:56Z","timestamp":1621570016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-021-05788-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,13]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["5788"],"URL":"https:\/\/doi.org\/10.1007\/s00213-021-05788-w","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,13]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}